<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">35738</article-id><article-id pub-id-type="doi">10.7554/eLife.35738</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-107291"><name><surname>Kane</surname><given-names>Melissa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107165"><name><surname>Rebensburg</surname><given-names>Stephanie V</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107166"><name><surname>Takata</surname><given-names>Matthew A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107167"><name><surname>Zang</surname><given-names>Trinity M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107168"><name><surname>Yamashita</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107169"><name><surname>Kvaratskhelia</surname><given-names>Mamuka</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-10194"><name><surname>Bieniasz</surname><given-names>Paul D</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2368-3719</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Laboratory of Retrovirology</institution>, <institution>Rockefeller University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Division of Infectious Diseases</institution>, <institution>University of Colorado Denver</institution>, <addr-line><named-content content-type="city">Denver</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution>Aaron Diamond AIDS Research Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-70124"><name><surname>Simon</surname><given-names>Viviana</given-names></name><role>Reviewing editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>pbieniasz@rockefeller.edu</email> (PB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>08</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e35738</elocation-id><history><date date-type="received"><day>08</day><month>02</month><year>2018</year></date><date date-type="accepted"><day>06</day><month>08</month><year>2018</year></date></history><permissions><copyright-statement>Â© 2018, Kane et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Kane et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-35738-v1.pdf"/><abstract><p>HIV-1 accesses the nuclear DNA of interphase cells via a poorly defined process involving functional interactions between the capsid protein (CA) and nucleoporins (Nups). Here, we show that HIV-1 CA can bind multiple Nups, and that both natural and manipulated variation in Nup levels impacts HIV-1 infection in a manner that is strikingly dependent on cell-type, cell-cycle, and cyclophilin A (CypA). We also show that Nups mediate the function of the antiviral protein MX2, and that MX2 can variably inhibit non-viral NLS function. Remarkably, both enhancing and inhibiting effects of cyclophilin A and MX2 on various HIV-1 CA mutants could be induced or abolished by manipulating levels of the Nup93 subcomplex, the Nup62 subcomplex, NUP88, NUP21, RANBP2, or NUP153. Our findings suggest that several Nup-dependent 'pathways' are variably exploited by HIV-1 to target host DNA in a cell-type, cell-cycle, CypA and CA-sequence dependent manner, and are differentially inhibited by MX2.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Investigator Award</award-id><principal-award-recipient><name><surname>Bieniasz</surname><given-names>Paul D</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R3764003</award-id><principal-award-recipient><name><surname>Bieniasz</surname><given-names>Paul D</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01AI100720</award-id><principal-award-recipient><name><surname>Yamashita</surname><given-names>Masahiro</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01AI062520</award-id><principal-award-recipient><name><surname>Kvaratskhelia</surname><given-names>Mamuka</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>F32AI116263</award-id><principal-award-recipient><name><surname>Kane</surname><given-names>Melissa</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-35738-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>